MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform ...
ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in ...
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results